Patched 1/PTCH Antibody [DyLight 405]

Novus Biologicals, part of Bio-Techne | Catalog # NBP1-71662V

Novus Biologicals, part of Bio-Techne

Key Product Details

Species Reactivity

Human, Mouse, Rat

Applications

Immunohistochemistry, Immunohistochemistry-Paraffin, Western Blot

Label

DyLight 405 (Excitation = 400 nm, Emission = 420 nm)

Antibody Source

Polyclonal Rabbit IgG

Concentration

Please see the vial label for concentration. If unlisted please contact technical services.

View all Patched 1/PTCH Antibodies »

Product Specifications

Immunogen

A genomic peptide made to a C-terminal region of the human Patched 1 protein (within residues 1200-1350). [Swiss-Prot Q13635]

Reactivity Notes

Rat reactivity reported in scientific literature (PMID: 30193838).

Localization

Membrane, Cytoplasm

Clonality

Polyclonal

Host

Rabbit

Isotype

IgG

Applications for Patched 1/PTCH Antibody [DyLight 405]

Application
Recommended Usage

Immunohistochemistry

Optimal dilutions of this antibody should be experimentally determined.

Immunohistochemistry-Paraffin

Optimal dilutions of this antibody should be experimentally determined.

Western Blot

Optimal dilutions of this antibody should be experimentally determined.
Application Notes
Optimal dilution of this antibody should be experimentally determined.

Formulation, Preparation, and Storage

Purification

Immunogen affinity purified

Formulation

50mM Sodium Borate

Preservative

0.05% Sodium Azide

Concentration

Please see the vial label for concentration. If unlisted please contact technical services.

Shipping

The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage

Store at 4C in the dark.

Background: Patched 1/PTCH

Patched 1 (PTCH1) acts as a receptor for SHH, IHH (indian hedgehog) and DHH (desert hedgehog) in SHH/sonic hedgehog signaling pathway which is critical in embryonic development, tissue patterning, and cell-fate decisions. SHH pathway activation is triggered by binding of SHH to PTCH1 (glycosylation being necessary for binding), which in the absence of SHH suppresses the activity of SMO (Smoothened protein), and this SHH- PTCH1 binding or mutational inactivation of PTCH1 relieves the inhibition of SMO culminating in the activation of one or more of GLI1 transcription factors that regulate the expression of downstream targets. PTCH1 mutations or its aberrant expression may leads to developmental defects and a cancer-prone phenotype. Mice partially deficient in functional PTCH1 exhibit developmental abnormalities that are comparable to those of nevoid basal cell carcinoma syndrome patients and additionally, these mice develop tumors such as medulloblastomas, rhabdomyosarcomas, and basal cell carcinomas following UV or ionizing radiation exposure. PTCH1 germline mutations in humans are responsible for nevoid basal cell carcinoma syndrome, also called Gorlin syndrome characterized by various developmental malformations and a high predisposition to skin basal cell carcinoma. Besides basal cell nevus syndrome (BCNS), defects in PTCH1 have been linked to sporadic basal cell carcinoma (BCC) and holoprosencephaly type 7 (HPE7).

Alternate Names

BCNS, HPE7, mes, NBCCS, ptc1, PTCH1

Gene Symbol

PTCH1

Additional Patched 1/PTCH Products

Product Documents for Patched 1/PTCH Antibody [DyLight 405]

Product Datasheets

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Download SDS

Product Specific Notices for Patched 1/PTCH Antibody [DyLight 405]



DyLight (R) is a trademark of Thermo Fisher Scientific Inc. and its subsidiaries.

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Privacy and Cookie Policy
Site Map
© Copyright 2024 Bio-Techne. All Rights Reserved.